en.Wedoany.com Reported - On June 18, South Korea's LG Chem announced a partnership with UK-based AI drug discovery company LabGenius Therapeutics, signing a joint development, option, and licensing agreement for multiple novel antibody-based anti-cancer drug candidates. LG Chem will leverage AI technology to accelerate the discovery of competitively differentiated anti-cancer drug substances and further enhance its artificial intelligence ecosystem for new drug development.
The collaboration focuses on tumor-targeting multispecific antibodies. The two parties will conduct research on targets related to difficult-to-treat solid tumors, aiming to screen next-generation antibody drug candidates with higher efficacy and lower toxicity. LG Chem will pay LabGenius an upfront fee and research costs, and will later decide whether to exercise options for further development and licensing based on joint research results.
LabGenius is a UK-based AI drug discovery biotechnology company whose core platform is EVA™. This platform integrates machine learning, high-throughput experimentation, robotic automation, and synthetic biology to optimize therapeutic antibodies, improving the efficiency of candidate antibody screening through a closed-loop "design-build-test-learn" process. Compared to traditional manual iterative design and experimental validation, such platforms can process more candidate structures in a shorter timeframe and feed experimental results back into the next round of model design.
The focus of LG Chem's collaboration is to shorten the early-stage discovery cycle for anti-cancer drugs. Antibody drugs have complex structures, and the process from target validation to lead optimization typically takes a long time, requiring candidates to balance efficacy, safety, selectivity, and developability. By incorporating LabGenius's AI and automated experimentation capabilities, LG Chem aims to more quickly identify drug candidates suitable for advancement to preclinical stages.
LG Chem's Life Sciences division is already advancing its AI drug development system. The company is building a comprehensive AI platform covering target discovery, drug candidate prediction, and efficacy screening, and plans to extend artificial intelligence further into clinical development, manufacturing, and process optimization. This partnership with LabGenius is a specific move to strengthen its anti-cancer drug R&D capabilities through external innovation.
For LabGenius, collaborating with LG Chem helps expand the application and validation of the EVA™ platform in the field of multispecific antibodies. The company has previously collaborated with several pharmaceutical companies on antibody optimization, and this project further directs its AI design capabilities toward oncology treatments. If the collaborative candidates enter subsequent development stages, LabGenius may also receive clinical, regulatory, and commercialization milestone payments, as well as royalties based on net sales.
Antibody drug development is becoming a key application area for AI-driven pharmaceuticals. Compared to small-molecule drugs, antibody design involves multiple variables such as protein structure, affinity, selectivity, immune response, and manufacturing feasibility, making it suitable for multi-objective optimization using machine learning and automated experimentation. Whether the collaboration between LG Chem and LabGenius can yield preclinical candidates will depend on model design quality, experimental validation results, candidate antibody safety, and the progress of option exercise.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
